Skip Navigation
Menu
Editorials |1 August 1995

Toxoplasmosis in AIDS: Keeping the Lid On

Joseph A. Kovacs, MD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
Copyright ©2004 by the American College of Physicians
2004
  • National Institutes of Health, Bethesda, MD 20892-1662 Requests for Reprints: Joseph A. Kovacs, MD, Building 10, Room 7D43, 10 Center Drive, MSC 1662, Bethesda, MD 20892-1662.
×
FULL TEXT
The management of toxoplasmic encephalitis in patients with human immunodeficiency virus (HIV) infection has been a continuously evolving process. Changes in management strategies have been made largely on the basis of clinical experiences, retrospective studies, and small, uncontrolled trials [1]. Currently, HIV-infected patients with neurologic symptoms, low CD4 counts (<100 cells/mm3), and compatible radiographic scans are usually treated empirically for Toxoplasma gondii encephalitis. Acute empiric therapy is usually initiated with either pyrimethamine-sulfadiazine or pyrimethamine-clindamycin [2, 3]; evidence of clinical improvement is seen within 1 to 2 weeks in most responding patients receiving these therapies [4, 5]. Acute therapy is continued until clinical and radiographic resolution occurs, which is usually within 3 to 6 weeks [1-5].
The combination of pyrimethamine plus sulfadiazine is the regimen of choice for acute therapy because it has been associated with a lower rate of failure due to disease progression than has pyrimethamine-clindamycin, although adverse reactions requiring discontinuation of therapy are common [1-3]. Leucovorin should always be coadministered with pyrimethamine to minimize toxicities. For acute therapy, 4 to 8 g of sulfadiazine and 50 to 75 mg of pyrimethamine per day are usually administered. Whether a regimen using lower drug doses is as effective but less toxic is currently unknown. As has been shown in controlled trials, pyrimethamine-clindamycin is clearly an efficacious and acceptable alternative [2, 3]. Other regimens with some activity in treating toxoplasmosis related to the acquired immunodeficiency syndrome (AIDS) include atovaquone, trimethoprim-sulfamethoxazole, pyrimethamine-dapsone, pyrimethamine-azithromycin, and...
FULL TEXT
PDF
Not Available
Citations
Citation

Kovacs JA. Toxoplasmosis in AIDS: Keeping the Lid On. Ann Intern Med. 1995;123:230–231. doi: 10.7326/0003-4819-123-3-199508010-00011

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 1995;123(3):230-231.

DOI: 10.7326/0003-4819-123-3-199508010-00011

4 Citations

Related Articles
Prophylaxis for Toxoplasmosis in AIDS
Annals of Internal Medicine; 117 (2): 163-164
Intermittent Trimethoprim-Sulfamethoxazole Compared with Dapsone-Pyrimethamine for the Simultaneous Primary Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis in Patients Infected with HIV
Annals of Internal Medicine; 122 (10): 755-761
Gastrointestinal Cytomegalovirus Disease
Annals of Internal Medicine; 119 (9): 924-935
Primary Cutaneous Tuberculosis after a Needlestick Injury from a Patient with AIDS and Undiagnosed Tuberculosis
Annals of Internal Medicine; 119 (7_Part_1): 594-595
View MoreView Less

Related Topics
Infectious Disease

Infectious Disease.

PubMed Articles
Robust control of HIV infection by antiretroviral therapy: a super-twisting sliding mode control approach.
IET Syst Biol 2019;13(3):120-128.
The first study on the usefulness of recombinant tetravalent chimeric proteins containing fragments of SAG2, GRA1, ROP1 and AMA1 antigens in the detection of specific anti-Toxoplasma gondii antibodies in mouse and human sera.
PLoS One 2019;14(6):e0217866.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×